Pfizer Beats Estimates With $16.6 Billion Revenue and $0.87 Adjusted EPS
Pfizer raised its 2026 revenue guidance to $62.0 billion to $64.0 billion and its adjusted EPS guidance to $2.95 to $3.05.
Pfizer PFE
Pfizer Inc · NYSE · Pharmaceutical Preparations
$30.67+0.49%close on Nov. 2, 2026 · volume 49.6M · Yahoo Finance
Price, last 50 sessions
Our coverage
Insider buying and selling
| Date | Insider | Trade | Shares | Avg. price | Value |
|---|---|---|---|---|---|
| Aug. 12, 2026 | Albert Bourla Chairman & CEO, director | Bought | 38,000 | $26.34 | $1.00 million |
| Aug. 5, 2026 | Jennifer B. Damico SVP & Controller | Sold | 3,278 | $25.40 | $83,261 |
| Aug. 5, 2026 | Ronald E. Blaylock director | Bought | 39,231 | $25.46 | $998,821 |
| Aug. 5, 2026 | Mortimer J. Buckley director | Bought | 37,632 | $25.52 | $960,369 |
Open-market purchases and sales reported on SEC Form 4 filed since July 24, 2026; grants, option exercises and shares withheld for tax aren't shown. A trade under a 10b5-1 plan was scheduled in advance. Where a filing was amended, the amendment's figures are shown.
Recent SEC filings
All 22 →Results of operations and financial condition · Financial statements and exhibits
AI summary, unreviewedPfizer Q3 2026 adjusted EPS of $0.87 beats $0.73 consensus on $16.6 billion revenue; full-year adjusted EPS guidance raised to $2.95-$3.05